Somatostatin
- Atc Codes:H01CB01
- CAS Codes:38916-34-6
- PHARMGKB ID:38916-34-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Somatin, Somatostatin; Belgium: Somatostatine; Bulgaria: Somatostatin; Cyprus: Somatostatin; Czech Republic: Somatostatin; France: Somatostatine; Germany: Somatostatin; Greece: Atostan, Eklivan, Sadolin, Somabion, Somargen, Somaritin, Somastin, Somatostatin, Sonafrine, Stilamin; Hungary: Somatostatin; Italy: Etaxene, Ikestatina, Modustatina, Resurmide, Somatostatin, Stilamin; Luxembourg: Modustine, Somatostatine, Stilamin; Netherlands: Somatostatine; Poland: Somatin, Somatostatin; Portugal: Somatostatina; Spain: Somatostatina, Somonal.
North America
Canada: Stilamin.
Latin America
Argentina: Somatostatina; Brazil: Stilamin.
Drug combinations
Chemistry
Somatostatin: C~76~H~104~N~18~O~19~S~2~. Mw: 1637.88. Growth hormone-release inhibiting factor. CAS-38916-34-6.
Pharmacologic Category
Hormones and Synthetic Substitutes; Somatotropin Antagonists. Hypothalamic Hormone. (ATC-Code: H01CB01).
Mechanism of action
A synthetic cyclic 14 aa peptide (identical in structure and activity to naturally-occurring somatostatin) which decreases splanchnic blood flow and portal venous pressure in man, possibly through direct action on unstriated muscle cells mediated by a calcium-dependent mechanism.
Therapeutic use
Symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of condition may be considered if necessary, once initial control established.
Pregnancy and lactiation implications
Use of somatostatin contraindicated in known or suspected pregnancy and during immediate post-partum period.
Unlabeled use
Contraindications
Hypersensitivity to the product, its excipients or recommended diluents.
Warnings and precautions
Caution when administering product to insulin-dependent diabetics in whom blood glucose should be measured every 3 to 4 hours. Simultaneous administration of insulin-requiring sugars should be avoided if possible. Insulin should be administered as necessary. Use in children should only be considered if potential benefits outweigh possible risks. As somatostatin has a short plasma half-life, the infusion must be maintained continuously once initiated. In the event that any interruption in the infusion occurs, a repeat bolus dose may be given to the patient, followed by resumption of the continuous infusion. The plasma half-life of somatostatin is increased in chronic renal disease, and its rate of clearance reduced. Somatostatin should therefore be administered to such patients with caution.